Showing all 7 results

• 
  Early human evidence

  AOD-9604

  £32.49
  5 mgBatch file pending

  A GH-derived metabolic fragment—not an incretin, amylin analogue or GH secretagogue.

  Available · 10 in stockAdd to basket
• 
  Clinical research

  Cagrilintide

  £64.00
  5 mgBatch file pending

  Targets amylin biology, making it mechanistically distinct from every incretin agonist in the category.

  UnavailableAsk about availability
• 
  Phase 2 clinical research

  MOTS-c

  £35.64
  Batch file pending

  MOTS-c begins inside mitochondria and is studied for cell-wide energy adaptation, rather than directly targeting appetite receptors.

  Available · 30 in stockAdd to basket
• 
  Phase 3 clinical research

  Retatrutide

  £49.99 – £209.99Price range: £49.99 through £209.99
  10 mg | 20 mg | 30 mg | 40 mg | 50 mg | 60 mgBatch file pending

  It is the only triple-receptor agonist in this catalogue: GIP, GLP-1 and glucagon.

  Available · 20 in stockAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Experimental

  Retatrutide + Cagrilintide

  £59.99
  5 mg + 5 mg | 10 mg + 10 mgBatch file pending

  It combines triple-receptor agonism with a separate amylin pathway, rather than adding another agent acting through the same…

  AvailableAdd to basket This product has multiple variants. The options may be chosen on the product page
• 
  Established

  Semaglutide

  £69.00
  5 mgBatch file pending

  A single-pathway GLP-1 comparator rather than a dual or triple incretin agonist.

  UnavailableAsk about availability
• 
  Established

  Tirzepatide

  £79.00
  10 mgBatch file pending

  Dual incretin agonism distinguishes it from single-target semaglutide and triple-target retatrutide.

  UnavailableAsk about availability